ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 894

Laboratory Tests in Giant Cell Arteritis – Do They Make the Cut?

Alexis Jones1, Joe Li2 and Charles Li3, 1Rheumatology, University College London, LONDON, United Kingdom, 2Rheumatology, Royal Surrey County Hospital, Guildford, United Kingdom, 3Royal Surrey County Hospital, Guildford, Great Britain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: biopsies, diagnosis, giant cell arteritis, laboratory tests and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The initial suspicion of Giant cell arteritis (GCA) is often made in the setting of primary care or casualty by a non-rheumatologist. Whilst temporal artery biopsy (TAB) is the gold standard for diagnosis, this is not readily available and can be difficult to organise outside a teaching hospital setting. Furthermore, the reliability of this test is reduced by concomitant steroid use and the presence of skip lesions in vessel wall inflammation. Clinical features combined with biochemical markers of inflammation are often the most important tools in the diagnosis of giant cell arteritis. In this study, we evaluate the association of CRP, ESR, platelet count and alkaline phosphatase (ALP) with the results of temporal artery biopsy in a regional setting involving three District General Hospitals in the UK. As it has been over 5 years since the British Society for Rheumatology guidelines were published, we also audited whether our local practice follows them. Particularly, with regard to biopsy length which has been shown to influence the sensitivity of the test.

Methods: A retrospective analysis of all patients referred with suspected temporal arteritis to three centres in South East England between Feb 2010 and May 2015 was performed. Data regarding age, sex, date of biopsy, length of biopsy, biopsy result and ESR, CRP, platelet count and Alkaline Phosphatase (ALP) within 14 days prior to biopsy was collected. 

Results: 542 patients were referred with suspected giant cell arteritis between Feb 2010 and May 2015. 119 patients were excluded owing to inconclusive biopsy findings and lack of laboratory results within 14 days prior to TAB. The majority of excluded patients had blood tests performed at other sites. 422 patients (131 men 291 women) were included. Mean age was 72.4. 95 TABS were positive and 327 negative.  Mean biopsy length was 13.9mm. 32.2% of biopsies were less than 10mm. The mean ESR for positive biopsies was 58.6 versus 40.1 in negative biopsies (p < 0.001 ). 84.3% of patients with a positive temporal artery biopsy were associated with an ESR >10. The mean CRP in those with positive biopsies was 91.1 compared with 50.3 in those with a negative TAB (p < 0.001). 95.8% of patients with a positive TAB had a CRP >10. Patients with positive TABS also had higher platelet counts: mean platelet count was 424 in positive biopsies versus 334 in negative biopsies (p < 0.001). There was no statistical difference in ALP between those with positive and negative biopsies.

Conclusion: Laboratory correlates of inflammation remain good predictors of a positive temporal artery biopsy. A positive biopsy is associated with increased CRP, ESR and platelets. Our study shows that improvements need to be made locally to ensure the recommended temporal artery biopsy length (>10mm) is taken.


Disclosure: A. Jones, None; J. Li, None; C. Li, None.

To cite this abstract in AMA style:

Jones A, Li J, Li C. Laboratory Tests in Giant Cell Arteritis – Do They Make the Cut? [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/laboratory-tests-in-giant-cell-arteritis-do-they-make-the-cut/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/laboratory-tests-in-giant-cell-arteritis-do-they-make-the-cut/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology